Sansure Biotech Inc. (SHA:688289)
19.92
-0.15 (-0.75%)
May 14, 2025, 2:44 PM CST
Sansure Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
Operating Revenue | 1,497 | 991.1 | 6,304 | 4,342 | 4,598 | Upgrade
|
Other Revenue | - | 16.02 | 146.58 | 172.86 | 164.99 | Upgrade
|
Revenue | 1,497 | 1,007 | 6,450 | 4,515 | 4,763 | Upgrade
|
Revenue Growth (YoY) | 48.60% | -84.39% | 42.88% | -5.22% | 1203.53% | Upgrade
|
Cost of Revenue | - | 280.96 | 2,912 | 1,283 | 971.99 | Upgrade
|
Gross Profit | 1,497 | 726.15 | 3,538 | 3,232 | 3,791 | Upgrade
|
Selling, General & Admin | - | 547.37 | 939.48 | 488.21 | 603.01 | Upgrade
|
Research & Development | - | 194.81 | 331.2 | 186.84 | 82.62 | Upgrade
|
Other Operating Expenses | 1,233 | 0.1 | 27.31 | 12.48 | 11.71 | Upgrade
|
Operating Expenses | 1,233 | 747.23 | 1,344 | 706.01 | 721.28 | Upgrade
|
Operating Income | 263.86 | -21.08 | 2,194 | 2,526 | 3,070 | Upgrade
|
Interest Expense | - | -2.41 | -2.09 | -0.83 | -0.51 | Upgrade
|
Interest & Investment Income | - | 308.41 | 48.35 | 32.53 | 33.06 | Upgrade
|
Currency Exchange Gain (Loss) | - | 4.31 | 5.04 | -42.25 | -43.71 | Upgrade
|
Other Non Operating Income (Expenses) | -17.57 | 0.87 | -7.94 | -1.61 | -0.7 | Upgrade
|
EBT Excluding Unusual Items | 246.29 | 290.11 | 2,237 | 2,513 | 3,058 | Upgrade
|
Impairment of Goodwill | - | - | -1.44 | - | - | Upgrade
|
Gain (Loss) on Sale of Investments | - | 61.84 | 79.24 | 81.01 | 6.23 | Upgrade
|
Gain (Loss) on Sale of Assets | - | -7.21 | -5.47 | 0.41 | 0.97 | Upgrade
|
Asset Writedown | - | - | -15.1 | - | - | Upgrade
|
Other Unusual Items | - | 65.73 | 21.3 | 21.37 | 5.13 | Upgrade
|
Pretax Income | 246.29 | 410.48 | 2,316 | 2,616 | 3,070 | Upgrade
|
Income Tax Expense | -12.74 | 62.31 | 379.21 | 373.68 | 453.56 | Upgrade
|
Earnings From Continuing Operations | 259.03 | 348.17 | 1,937 | 2,243 | 2,617 | Upgrade
|
Minority Interest in Earnings | - | 15.55 | 0.09 | 0.17 | - | Upgrade
|
Net Income | 259.03 | 363.72 | 1,937 | 2,243 | 2,617 | Upgrade
|
Net Income to Common | 259.03 | 363.72 | 1,937 | 2,243 | 2,617 | Upgrade
|
Net Income Growth | -28.78% | -81.22% | -13.64% | -14.29% | 6527.90% | Upgrade
|
Shares Outstanding (Basic) | 589 | 587 | 585 | 589 | 552 | Upgrade
|
Shares Outstanding (Diluted) | 589 | 587 | 585 | 589 | 552 | Upgrade
|
Shares Change (YoY) | 0.35% | 0.26% | -0.59% | 6.55% | 3.97% | Upgrade
|
EPS (Basic) | 0.44 | 0.62 | 3.31 | 3.81 | 4.74 | Upgrade
|
EPS (Diluted) | 0.44 | 0.62 | 3.31 | 3.81 | 4.74 | Upgrade
|
EPS Growth | -29.03% | -81.27% | -13.12% | -19.56% | 6274.83% | Upgrade
|
Free Cash Flow | - | -347.81 | 2,000 | 1,504 | 2,534 | Upgrade
|
Free Cash Flow Per Share | - | -0.59 | 3.42 | 2.56 | 4.59 | Upgrade
|
Dividend Per Share | - | 0.462 | 1.298 | 0.760 | 0.760 | Upgrade
|
Dividend Growth | - | -64.39% | 70.77% | - | - | Upgrade
|
Gross Margin | 100.00% | 72.10% | 54.85% | 71.58% | 79.59% | Upgrade
|
Operating Margin | 17.63% | -2.09% | 34.01% | 55.94% | 64.45% | Upgrade
|
Profit Margin | 17.31% | 36.12% | 30.03% | 49.68% | 54.94% | Upgrade
|
Free Cash Flow Margin | - | -34.53% | 31.01% | 33.32% | 53.19% | Upgrade
|
EBITDA | 363.46 | 78.53 | 2,269 | 2,571 | 3,096 | Upgrade
|
EBITDA Margin | 24.29% | 7.80% | 35.18% | 56.96% | 65.01% | Upgrade
|
D&A For EBITDA | 99.61 | 99.61 | 75.47 | 45.89 | 26.68 | Upgrade
|
EBIT | 263.86 | -21.08 | 2,194 | 2,526 | 3,070 | Upgrade
|
EBIT Margin | 17.63% | -2.09% | 34.01% | 55.94% | 64.45% | Upgrade
|
Effective Tax Rate | - | 15.18% | 16.37% | 14.28% | 14.77% | Upgrade
|
Revenue as Reported | - | 1,007 | 6,450 | 4,515 | 4,763 | Upgrade
|
Advertising Expenses | - | 26.28 | 36.36 | 32.38 | 27.94 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.